Features like CBT modules or gamification that reward hitting protein targets keep patients on the medication longer, making the platform more valuable
(jofem.org) The best-case signal: modest weight loss in a shorter trial A frequently cited 12-week randomized trial result (as summarized in reviews) reported: ~2.6 kg average loss with AOD-9604 1 mg/day vs ~0.8 kg with placebo (PMC) This is the kind of result that can be statistically meaningful, clinically modest, and very sensitive to study design (diet, activity, baseline metabolic status, adherence)
doi: 10.4049/jimmunol.169.2.1126
World J Biol Psychiatry 14:334385 Bella R, Biondi R, Raffaele R, Pennisi G (1990) Effect of acetyl-l-carnitine on geriatric patients suffering from dysthymic disorders
A smaller subset (about 47% of trial participants) experience GI side effects severe enough to discontinue treatment